Navigation Links
Pharmaceutical Companies On Defense As Post-ACA Implementation Continues
Date:4/22/2013

provider relationships with data sets nationally. It is the first—and only—database of its kind.  In one comprehensive solution, pharmaceutical executives can easily identify the interconnectedness of a particular market, allowing them to save time and make smart decisions. HealthCare Network Manager has a NEW mobile-friendly interface and dynamic search capabilities.

About HealthLeaders-InterStudyHealthLeaders-InterStudy, a Decision Resources Group company, is the authoritative source for managed care data, analysis, and news. HealthLeaders-InterStudy is part of the Market Access Business Unit at Decision Resources Group which also includes Abacus International, Fingertip Formulary, Pinsonault, and PharmaStrat. Find out more at www.hl-isy.com.

About Decision Resources GroupDecision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Lydia Smith

Elizabeth MarshallHealthLeaders-InterStudy

Decision Resources Group 781-993-2594

781-993-2563 lsmith@dresources.com

emarshall@dresources.com


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
2. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
3. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
4. Biopharmaceutical Managed Care Strength Closely Intertwined with Marketplace Success
5. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
6. Comparison of Biopharmaceutical Industry Between China and India 2013
7. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
8. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
9. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
10. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
11. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Quebec , March 27, 2015  Valeant Pharmaceuticals ... today the closing of its previously announced registered offering ... (the "Offering"). Pursuant to the Offering, the ... $199.00 per share, for aggregate gross proceeds of approximately ... with the U.S. Securities and Exchange Commission a final ...
(Date:3/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... announced that they have entered into an ... proprietary sd-rxRNA® technology for use in developing ... the potential to result in novel, more ... could be a significant step toward personalized ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Calif., Aug. 12 Founder of the Dermatology Institute, Peter Rullan, ... Perfect™ treatments to his patients with the purchase of the ... excited to add this new service for our patients," Dr. Rullan ... wanted to find a system that not only met my patients, ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: www.pdl.com . ... logo are considered trademarks of PDL BioPharma, Inc. ... release contains forward-looking statements. Each of these forward-looking statements ... from those, express or implied, in these forward-looking statements. ...
Cached Medicine Technology:Chula Vista's Dr. Peter Rullan Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2PDL BioPharma Receives Letter from Genentech Relating to European Patents 2
(Date:3/28/2015)... 2015 Lately the student-athlete experience ... changes and proposals around the NCAA. In a March ... collegiate student-athletes across a spectrum of universities and sports ... challenges. The special panel consists of athletes who have ... from football, track and field, baseball, and volleyball. They ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 The ... method of sustainable health. After 18 years of research ... including professional UFC contenders, Dr. Jon Petrick is excited ... , Just some of the immediate benefits of this ... vitality, increased levels of strength of the immune system, ...
(Date:3/28/2015)... March 28, 2015 Purity Products®, ... supplements announces the release of their revolutionary new ... in two randomized, double-blind, placebo-controlled clinical studies to ... and hip size. MuffinStop™ is a combination of ... Garcinia mangostana, fused together to create one of ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership ... care provider for the 2015 and 2016 season. As the ... and an athletic trainer for the team throughout each season. ... against the Cleveland Gladiators at Amalie Arena; the game starts ... to us as it gives us the opportunity, to provide ...
Breaking Medicine News(10 mins):Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3
... Novavax Inc. (Nasdaq: NVAX) announced ... 12.5 million shares of Novavax,s common stock at $0.88 per share ... the new strategic alliance between Novavax and Cadila. Novavax intends to ... pay a portion of its 4.75% senior convertible notes due in ...
... that it reduces replication of the virus, , , WEDNESDAY, ... help people with HIV who don,t respond to standard ... the "gold standard" treatment for HIV is known as ... a number of drugs that reduce viral load by ...
... America (HFA) announces the publication of Living ... addition to HFA,s Living With Grief(R) book series. ... is a compilation of chapters by well-known experts in grief ... end-of-life decision making, shapes attitudes around the experience of terminal ...
... Albert Einstein College of Medicine of Yeshiva University have proposed ... brains of people with autism are structurally normal but dysregulated, ... , The central tenet of the theory, published in the ... autism is a developmental disorder caused by impaired regulation of ...
... schizoaffective disorder who received paliperidone extended release tablets ... in a broad range of schizoaffective symptoms, according ... 12th International Congress on Schizophrenia Research (ICOSR) in ... provide additional evidence for symptomatic improvement of schizoaffective ...
... April 1st, Professional Healthcare Resources celebrates 15 years of ... The company was started in 1994 by Eileen DeCesare ... an organization offering home health, hospice, and personal care ... The company has over 700 employees and eight branch ...
Cached Medicine News:Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2Health News:New HIV Drug May Help Those Resistant to Therapy 2Health News:Hospice Foundation of America Publishes New Book on Diversity and End-of-Life Care 2Health News:Einstein scientists propose new theory of autism 2Health News:Einstein scientists propose new theory of autism 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 7Health News:Professional Healthcare Resources Celebrates 15 Year Anniversary 2
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: